Inflammation is commonly believed to be a culprit in Alzheimer disease pathogenesis. Recent studies, however, indicate that certain aspects of the inflammatory response may have therapeutic potential (pages 612–618).
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Identification of candidate DNA methylation biomarkers related to Alzheimer’s disease risk by integrating genome and blood methylome data
Translational Psychiatry Open Access 13 December 2023
-
RIG-1 receptor expression in the pathology of Alzheimer’s disease
Journal of Neuroinflammation Open Access 02 April 2014
-
Independent component analysis of Alzheimer's DNA microarray gene expression data
Molecular Neurodegeneration Open Access 28 January 2009
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
McGeer, E.G. & McGeer, P.L. The importance of inflammatory mechanisms in Alzheimer Disease. Exp. Gerontol. 33, 371–378 (1998).
Wyss-Coray, T. et al. TGF-β1 promotes microglia amyloid-β clearance and reduces plaque burden in transgenic mice. Nature Med. 7, 612–618 (2001).
Gonzalez-Scarano, F. & Baltuch, G. Microglia as mediators of inflammatory and degenerative diseases. Annu. Rev. Neurosci. 22, 219–240 (1999).
Yankner, B.A. Mechanisms of neuronal degeneration in Alzheimer's Disease. Neuron 16, 921–932 (1996).
Schenk, D. et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173–177 (1999).
Bacskai, B.J. et al. Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nature Med. 7, 369–372 (2001).
Bard, F. et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Med. 6, 916–919 (2000).
Janus, C. et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979–982 (2000).
Morgan, D. et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982–985 (2000).
Rogers, J. et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 43, 1609–1611 (1993).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Weninger, S., Yankner, B. Inflammation and Alzheimer disease: The good, the bad, and the ugly. Nat Med 7, 527–528 (2001). https://doi.org/10.1038/87839
Issue Date:
DOI: https://doi.org/10.1038/87839
This article is cited by
-
Identification of candidate DNA methylation biomarkers related to Alzheimer’s disease risk by integrating genome and blood methylome data
Translational Psychiatry (2023)
-
RIG-1 receptor expression in the pathology of Alzheimer’s disease
Journal of Neuroinflammation (2014)
-
Neuropathology after active Aβ42 immunotherapy: implications for Alzheimer’s disease pathogenesis
Acta Neuropathologica (2010)
-
Independent component analysis of Alzheimer's DNA microarray gene expression data
Molecular Neurodegeneration (2009)
-
Alzheimer’s disease, brain immune privilege and memory: a hypothesis
Journal of Neural Transmission (2006)